Drug safety funds
Drug safety oversight would have funding of $40 million under an amendment Senate Health Committee Chairman Ted Kennedy, D-Mass., successfully proposed to the Senate budget plan March 23. The resolution outlines a budget blueprint for congressional appropriations. Kennedy and committee ranking Republican Michael Enzi, Wyo., cosponsored the most prominent pending drug safety bill in the Senate, S 484 (1"The Pink Sheet" March 26, 2007, p. 4). The Senate cleared its budget plan March 23 and the House passed its version March 29; a conference committee will resolve differences between the two bills after the mid-April congressional recess...
You may also be interested in...
FDA should revisit the post-marketing studies that firms have outstanding, eliminate many of them, and set firm deadlines for the remaining trials, academics suggested at a March 22 hearing by the House Energy and Commerce/Oversight and Investigations Subcommittee
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.